Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy  by Bos, Hendrik et al.
Kidney International, Vol. 57, Suppl. 75 (2000), pp. S-32–S-37
Role of patient factors in therapy resistance to antiproteinuric
intervention in nondiabetic and diabetic nephropathy
HENDRIK BOS, STEEN ANDERSEN, PETER ROSSING, DICK DE ZEEUW, HANS-HENRIK PARVING,
PAUL E. DE JONG, and GERJAN NAVIS
Department of Clinical Pharmacology and Division of Nephrology, University Hospital, Groningen, The Netherlands and
Steno Diabetes Center, Gentofte, Denmark
Role of patient factors in therapy resistance to antiproteinuric dicts long-term renoprotective efficacy in man [4] as well
intervention in nondiabetic and diabetic nephropathy. Reduc- as in experimental renal disease [5]. In studies of parallel
tion of proteinuria is a prerequisite for successful long-term design, the treatment group with more effective reduc-renoprotection. To investigate whether individual patient fac-
tion of proteinuria invariably shows more effective reno-tors are determinants of antiproteinuric efficacy, we analyzed
protection, suggesting that the antiproteinuric efficacy ofindividual responses to different modes of antiproteinuric in-
tervention in nondiabetic and diabetic patients, obtained in specific drugs is crucial to their long-term renoprotective
prior studies comparing the efficacy of various pharmacological potential [6]. Moreover, it has been noted that the pa-
regimens. The individual antiproteinuric response to angioten-
tient-to-patient variability in antiproteinuric response issin-converting enzyme (ACE) inhibition positively correlated
large and that the individual antiproteinuric responseto the response to angiotensin type I (AT1) receptor blockade
in diabetic (r 5 0.67, P , 0.01, N 5 16) as well as nondiabetic appears to predict long-term renoprotection, irrespective
patients (r 5 0.75, P , 0.01, N 5 12). This corresponded to the class of drug that is used, in nondiabetic [6, 7] as
the correlations for antihypertensive efficacy between ACE well as diabetic patients [8, 9]. The latter observationinhibition and AT1 receptor blockade in diabetic (r 5 0.73, P ,
suggests that patient factors may be relevant determi-0.001) as well as nondiabetic patients (r 5 0.55, P , 0.05).
nants of therapy response. If so, one would expect thatRemarkably, the antiproteinuric response to ACE inhibition
also correlated positively to the antiproteinuric response to the renal response to intervention therapy would be
indomethacin (r 5 0.63, P , 0.05, N 5 9). Thus, patients more or less consistent for a given individual, irrespective
responding favorably to one class of antiproteinuric drugs also
the mode of intervention. To test this hypothesis, werespond favorably to other classes of available drugs, support-
analyzed the individual responses to different modes ofing a main role for individual patient factors in responsiveness
or resistance to antiproteinuric intervention. In the search for antiproteinuric intervention (i.e., ACE inhibition vs.
strategies to improve response in these high risk patients, com- AT1 receptor blockade and ACE inhibition vs. the non-
bination-treatment (combining different drugs, and combining steroidal anti-inflammatory drug [NSAID] indometha-drugs with dietary measures like sodium and protein restric-
cin), as obtained in previous studies in diabetic and non-tion), and the use of higher doses may provide more fruitful
diabetic renal patients, comparing the efficacy of variousstrategies to optimize renoprotection than shifting to other
classes of the available drugs. pharmacological regimens.
PATIENTS AND METHODSMajor progress has been made during the last decade
The studies in which the patients presented here tookin the prevention of progressive loss of renal function
in chronic renal disease. Perhaps the most significant part have been published previously [10, 11]. Data com-
advance is that it has become clear that the rate of loss of paring the efficacy of ACE-inhibitor enalapril (10 and
renal function can be effectively retarded by intervention 20 mg/day) and AT1-receptor antagonist (AIIA) losartan
therapy in diabetic [1] as well as nondiabetic renal dis- (50 and 100 mg/day) were derived from [10] for patients
ease [2]. Reduction of proteinuria appears to play a prin- with nondiabetic proteinuria and from [11] for diabetic
cipal role in the prevention of progressive loss of renal nephropathy in IDDM, respectively. In addition, we ana-
function [3], as reduction of proteinuria consistently pre- lyzed individual data on the antiproteinuric efficacy of
ACE inhibitor lisinopril vs. the NSAID indomethacin
(75 mg twice daily) from 9 patients with nondiabeticKey words: proteinuria, ACE inhibition, AT1 receptor blockade,
NSAIDs proteinuria [12]. In this study, to avoid differences in
blood pressure between the lisinopril and the indometha-Ó 2000 by the International Society of Nephrology
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Table 1. Group values for mean arterial pressure, albuminuria, proteinuria, and plasma renin activity
Losartan Enalapril
Patients Untreated 50 mg 100 mg 10 mg 20 mg
IDDM (N 5 16)
MAP mm Hg 10466 9566 9668 98618 9369
Albuminuria mg/24 h 1127 784 513 677 528
609–3054 419–1457 310–1675 254–1649 158–1366
PRA mU/L 26 51.8 48.5 67.2 74.1
12.4–33.7 18–130.2 27–184.5 20.3–123.5 34.3–244.9
NDRD (N 5 12)
MAP mm Hg 11468 10067 9769 100612 9366a
Proteinuria g/24 h 4.5 3.3 2.9 2.4 1.6
2.6–8.4 1.9–4.1 1.1–4.0 1.3–4.6 1.1–3.6
PRA nmolAI/L/h* 1.7 4.9 6.4 6.4 10.4
0.8–3.3 2.4–8.3 3.8–8.6 3.4–9.7 6.6–14.1
Abbreviations are: MAP, mean arterial pressure; IDDM, insulin-dependent diabetes mellitus; NDRD, nondiabetic renal disease; PRA, plasma renin activity. Data
on MAP are given as means 6 SD; data on albuminuria, proteinuria and PRA are given as median and 95% CI.
aData from 11/12 patients
Table 2. Group values for mean arterial pressure and proteinuriacin regimen, the latter was used in combination with
in 9 patients with nondiabetic proteinuria
conventional antihypertensive medication, i.e, alpha-
Indomethacin 1methyldopa or clonidine. Lisinopril dose was 10 mg.
conventionalData on glomerular protein leakage are given as 24-hour Untreated Lisinopril antihypertensives
albumin excretion in diabetic patients and as 24-hour
Mean arterial pressure
protein excretion in nondiabetic patients. Blood pressure mm Hg 106613 8865 95610
Proteinuria g/24 h 8.1 1.9 1.4data reflect Dinamap measurements obtained after 15
2.9–10.1 0.9–5.6 1–5.8minutes in supine position in the nondiabetic patients,
Data on mean arterial pressure are given as means 6 SD, data on proteinuriaand the mean of 24-hour values obtained by Ambulatory
are given as median and 95% CI.
Blood Pressure Measurement in the diabetic patients.
In the studies comparing ACE inhibitor with AT1
receptor blockade two doses of both drugs were used.
To test for individual factors in therapy response, we ACE inhibition as compared to AT1 receptor blockade
compared the individual responses for the doses of ACE are given in Table 1. ACE inhibition and AT1 receptor
inhibitor and AT1 receptor blocker estimated to be ap- blockade reduced urinary protein leakage as well as
proximately equipotent for antiproteinuric effect at group blood pressure in diabetic as well as nondiabetic patients.
level. In the nondiabetic patients median proteinuria was Group values for nondiabetic patients in whom the effect
reduced by 31% (95% CI: 7–43) and 46% (95% CI: of lisinopril was compared with indomethacin combined
15–53) by 50 and 100 mg losartan, respectively, and by with conventional antihypertensive treatment are given
45% (95% CI: 16–57) and 57% (95% CI: 23–74) by 10 in Table 2, showing that both regimens reduced protein-
and 20 mg enalapril, respectively. In the diabetic patients uria as well as blood pressure.
median albuminuria was reduced by 32% (95% CI: 11– The individual responses of urinary protein loss during
54) and 42% (95% CI: 23–60) by 50 and 100 mg losartan, ACE inhibition as compared to the other regimens are
respectively, and by 36% (95% CI: 15–72) and 57% given in Fig. 1 for diabetic and nondiabetic patients. The
(95% CI: 22–76) by 10 and 20 mg enalapril, respectively. responses to ACE inhibition and AT1 receptor blockade
Thus, 20 mg enalapril appeared to be somewhat more were significantly correlated; this was true for the popula-
potent; this was also supported by trough PRA measure-
tions analyzed together (r 5 0.67; N 5 28; P , 0.001)ments (Table 1). Therefore, we compared the individual
as well as for diabetic (r 5 0.67; N 5 16, P , 0.01) andresponses to 100 mg losartan with those to 10 mg enalapril
nondiabetic subjects separately (r 5 0.75; N 5 12, P ,for diabetic as well as nondiabetic patients.
0.01). Remarkably, the individual response-relation be-Data on blood pressure are given as mean 6 SD; data
tween ACE inhibition and NSAID indomethacin (Fig. 1;on urinary protein loss and PRA are given as medians
squares [r 5 0.63, N 5 9, P , 0.05]) fitted well intoand 95% CI.
the relation between ACE inhibition and AT1 receptor
blockade. The responses of blood pressure to ACE inhi-
RESULTS bition and AT1 receptor blockade (Fig. 2) were posi-
tively correlated as well for all patients analyzed togetherGroup values for blood pressure, urinary protein loss
and PRA in the different study populations treated with (r 5 0.70; P , 0.001) as well as for diabetic (r 5 0.73;
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Fig. 2. Individual antihypertensive efficacy presented as percentageFig. 1. Individual antiproteinuric efficacy. In diabetic patients (IDDM),
change in diabetic patients (IDDM; d) and in nondiabetic renal diseaseefficacy is presented as percentage change in albuminuria. In nondia-
(NDRD; m, ACE inhibitor vs. AT1 receptor blockade; j, ACE inhibi-betic patients (NDRD), efficacy is presented as percent change in pro-
tor vs. NSAID combined with alpha-methyldopa).teinuria. Symbols are: (d), ACE inhibitor vs. AT1 receptor blockade in
IDDM; (m), ACE inhibitor vs. AT1 receptor blockade in NDRD; (j),
ACE inhibitor vs. NSAID combined with alpha-methyldopa in NDRD.
sure, and with the renin-angiotensin system at different
levels, but also to the comparison of antiproteinuric effi-
P , 0.001) and nondiabetic subjects separately (r 5 0.55; cacy of ACE inhibition and NSAID, i.e., drugs with a
P , 0.05). The correlation between the blood pressure different mechanism of action.
response to lisinopril and the NSAID/alphamethyldopa These data provide evidence that individual factors
regimens did not quite reach statistical significance (r 5 are involved in the responsiveness to antiproteinuric
0.55, P 5 0.06) in this small number of patients. No correla- therapy, irrespective of the mode of pharmacological
tion was present between antiproteinuric response and intervention. Blockade of the renin-angiotensin system
baseline albuminuria and proteinuria, respectively. by either ACE inhibition or AT1 receptor blockade re-
The individual antiproteinuric responses to the two duces blood pressure as well as proteinuria. The individ-
doses of ACE inhibitor and AT1 receptor blocker are ual consistency in responsiveness to ACE inhibition and
given in Fig. 3 for diabetic and nondiabetic patients. AT1 receptor blockade applied to the responses of uri-
The individual responses to the two different doses were nary protein leakage as well as of blood pressure. The
positively correlated for enalapril in nondiabetic (r 5 individual consistency of the antiproteinuric response
0.74, P , 0.01) and diabetic patients (r 5 0.59, P , 0.05). to ACE inhibition and NSAID suggests that individual
A similar correlation was found for the response to the responsiveness to antiproteinuric therapy could also be
two doses of losartan in nondiabetic patients (r 5 0.69,
a specific renal characteristic and not secondary to indi-
P , 0.01), whereas in diabetic patients the correlation
vidual blood pressure responsiveness. However, in thisdid not quite reach statistical significance (r 5 0.31).
respect our data are not entirely conclusive, because in
the study analyzed here, the NSAID was combined with
DISCUSSION conventional antihypertensives to obtain satisfactory
blood pressure control.This analysis demonstrates that the antiproteinuric re-
The individual consistency of antiproteinuric responsesponse to different classes of drugs is remarkably con-
similarly applied to nondiabetic and diabetic patients.stant for individual patients in diabetic as well as nondia-
Thus, the underlying renal diagnosis is apparently not abetic renal disease. Remarkably, this not only applies to
main factor in the individual likelihood to respond tothe comparison of efficacy of ACE inhibition and AT1
receptor blockade, i.e., drugs interfering with blood pres- intervention therapy. As we reviewed previously, the
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Fig. 3. Individual antiproteinuric responses to the two different doses of ACE inhibitor (A) and AT1 receptor blockade (B) for diabetic (IDDM, d)
and nondiabetic patients (j). The continuous line represents the line of identity.
determinants of progressive loss of renal function display from one class of drug to another, which seems at vari-
ance with our findings in the present renal populations.a striking similarity for diabetic and nondiabetic renal
patients and, morever, the predictors of effective reno- This seeming discrepancy may be due to greater differ-
ences in mechanisms of therapy resistance in essentialprotection are similar as well [13]. The present data fur-
ther extend this similarity. Moreover, they demonstrate hypertension as compared to our renal populations, or
to greater differences in mechanisms of action betweenthat the findings are not limited to a single center.
Our data indicate that therapy resistance in renal pa- the classes of drugs used.
Our data indicate that patients with a favorable anti-tients is related to individual, patient-related factors. To
improve treatment in high-risk patients, elucidation of proteinuric response to one class of drugs can also be
expected to respond favorably to the other availablethese individual factors would be of great importance.
The severity of prior renal damage could be involved as antiproteinuric drugs. Thus, in patients experiencing side
effects such as cough or rash during ACE-inhibition,suggested by recent findings in renal transplant recipients
in whom more severe tubulointerstitial and vascular dam- treatment can be switched to another class of drug with-
out losing therapeutic efficacy. However, our findingsage predicted a poor antiproteinuric response to ACE
inhibition [14]. A higher baseline proteinuria was also also indicate that in individuals with a poor antiprotein-
uric response to one class of drug, no major improvementreported to be associated with a less effective response
to long-term ACE inhibition [15] but in our data-sets no in efficacy can be expected from switching to other drugs.
As a poor antiproteinuric response predicts a poor long-such relationship was present. Genetic factors may be
involved in response variability as well. The ACE (I/D) term renal prognosis, it would be important to avail of
other strategies to optimize antiproteinuric response inpolymorphism has been identified as a determinant of
progressive loss of renal function [16, 17] and of therapy these patients. Fortunately, several options are available
to enhance antiproteinuric response in individual pa-responsiveness [18, 19] in nondiabetic as well as diabetic
renal patients. tients. The antiproteinuric response to ACE inhibition
can be enhanced by dietary sodium restriction [21] andIn line with our data, a recent study of essential hyper-
tension demonstrated the importance of individual fac- by addition of a diuretic [22], measures that also improve
blood pressure response. In this respect, it is relevant totors for therapy response [20]. However, in this study the
proportion of responders could be increased by switching note that we previously observed an individually deter-
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and long term antiproteinuric response to inhibition of renin angio-mined response pattern to ACE inhibition in essential
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6. The GISEN Group: Randomised placebo-controlled trial of effectprotein diet [24], or with NSAID [25] therapy can selec-
of ramipril on decline in glomerular filtration rate and risk oftively improve antiproteinuric efficacy. Thus, in poor
terminal renal failure in proteinuric non-diabetic patients. Lancet
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7. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiprotein-over switching to another class of drug. Other therapeu-
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